REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH(+) CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT